Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Abnova
Taipei, Taiwanabnova.com ↗
- Ownership
- Private
- Employees
- ~53
- Development stage
- Other
01
Overview
Abnova has the world’s largest capacity for monoclonal and polyclonal antibody production using genomic/proteomic platforms and offers a broad catalog of humanized antibodies, recombinant proteins, and diagnostic reagents; they support cancer immunotherapy, biomarker discovery, diagnostics, and automation solutions for life science research and clinical diagnostics.
- Therapeutic areas
- OtherOncology
- Modalities
- Monoclonal antibodyPolyclonal antibodyRecombinant proteinNanobody therapymRNA-based drugs (service support, e.g. nanoCAR-T mRNA Service)
- Industry
- Chemicals & Materials
02
Partnerships
Companion diagnostic development for lung cancer (with global companies, details not specified)Non-invasive prenatal diagnosis collaborations
Beyond the preview
Go deeper on Abnova.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abnova.